Early control of C-reactive protein levels with non-biologic is associated with slow radiographic progression in radiographic axial spondyloarthritis, according to a recent study published in the International Journal of Rheumatic Diseases.
Predicting radiographic progression is vital for assessing the prognosis of patients with radiographic axial spondyloarthritis, and C-reactive protein (CRP) may be a valuable biomarker for this purpose. This study aimed to investigate the relationship between changes in the CRP level and spinal radiographic progression in patients with radiographic axial spondyloarthritis who were initially treated with non-biologics.
Patients with radiographic axial spondyloarthritis who were followed up for 18 years at a single centre and initially treated with nonsteroidal anti-inflammatory drugs and/or conventional disease-modifying antirheumatic drugs for 3 months were included. Patients with a CRP level of <0.8 mg/dL or 50% of the baseline CRP at 3 months were assigned to the controlled CRP group (n = 351), and the remaining patients were assigned to the uncontrolled CRP group (n = 452). A generalized estimating equation was used to analyze the differences in the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) between the 2 groups.
The results of the study are as follows:
The increase in the mSASSS was slower in the controlled CRP group than in the uncontrolled CRP group (interaction term β = -.499, 95% confidence interval -0.699 to -0.300).
Thus, the researchers concluded that controlled CRP achieved in response to initial treatment with non-biologic agents for 3 months was significantly associated with a slower rate of spinal radiographic change in patients with radiographic axial spondyloarthritis. The CRP level at 3 months after initial non-biologic treatment is a good predictor of radiographic progression.
Reference:
Early control of C-reactive protein levels with non-biologic is associated with slow radiographic progression in radiographic axial spondyloarthritis by Bon San Koo et. al published in the International Journal of Rheumatic Diseases
https://pubmed.ncbi.nlm.nih.gov/34935282/